tetano
Editor, Senior Moderator
Immun Inflamm Dis
. 2023 Jun;11(6):e874.
doi: 10.1002/iid3.874. Cord blood antibodies following BBIBP-CorV (Sinopharm) vaccination during pregnancy
Sedigheh Hantoushzadeh[SUP] 1 [/SUP], Nasim Eshraghi[SUP] 1 [/SUP], Sarang Younesi[SUP] 2 [/SUP], Mohammadreza Salehi[SUP] 3 [/SUP], Nima Rezaei[SUP] 4 [/SUP], Mohammad Mehdi Hasheminejad[SUP] 1 [/SUP], Pegah Rashidian[SUP] 1 [/SUP], Saeedeh Shirdel[SUP] 1 [/SUP], Fatemeh Asadi[SUP] 1 [/SUP], Marjan Ghaemi[SUP] 1 [/SUP]
Affiliations
Objective: This study aimed to evaluate the maternal and umbilical cord blood antibody levels, after COVID vaccination during pregnancy.
Method: The women who received the COVID-19 vaccine (Sinopharm) during pregnancy were included. Maternal and cord blood samples were tested to detect the severe acute respiratory syndrome coronavirus 2 receptor binding domain (RBD) specific antibodies. In addition, obstetric information and side effects after vaccination were gathered.
Result: A total of 23 women were included. Eleven pregnant women took two doses and 12 cases received a single dose of the vaccine. No IgM antibody was detected in any maternal blood or cord blood samples. The RBD-specific Immunoglobulin G (IgG) antibody was positive in mothers receiving 2 doses of the vaccine and their infants. But the antibody titers were under the positive cut-off threshold for the other 12 women who were vaccinated with a single dose. Women who received both doses of vaccine had significantly higher IgG levels than a single dose of Sinopharm (p = .025). The same result was demonstrated in infants born to these mothers (p = .019).
Conclusion: There was a significant correlation between maternal and neonatal IgG concentrations. Although, receiving both doses of the BBIBP-CorV vaccine (not 1 dose) during pregnancy is highly beneficial for increasing humoral immunity for the mother and fetus.
Keywords: COVID-19; Iran; Sinopharm; antibody; cord blood; maternal mortality; pregnancy; vaccine.
. 2023 Jun;11(6):e874.
doi: 10.1002/iid3.874. Cord blood antibodies following BBIBP-CorV (Sinopharm) vaccination during pregnancy
Sedigheh Hantoushzadeh[SUP] 1 [/SUP], Nasim Eshraghi[SUP] 1 [/SUP], Sarang Younesi[SUP] 2 [/SUP], Mohammadreza Salehi[SUP] 3 [/SUP], Nima Rezaei[SUP] 4 [/SUP], Mohammad Mehdi Hasheminejad[SUP] 1 [/SUP], Pegah Rashidian[SUP] 1 [/SUP], Saeedeh Shirdel[SUP] 1 [/SUP], Fatemeh Asadi[SUP] 1 [/SUP], Marjan Ghaemi[SUP] 1 [/SUP]
Affiliations
- PMID: 37382259
- DOI: 10.1002/iid3.874
Objective: This study aimed to evaluate the maternal and umbilical cord blood antibody levels, after COVID vaccination during pregnancy.
Method: The women who received the COVID-19 vaccine (Sinopharm) during pregnancy were included. Maternal and cord blood samples were tested to detect the severe acute respiratory syndrome coronavirus 2 receptor binding domain (RBD) specific antibodies. In addition, obstetric information and side effects after vaccination were gathered.
Result: A total of 23 women were included. Eleven pregnant women took two doses and 12 cases received a single dose of the vaccine. No IgM antibody was detected in any maternal blood or cord blood samples. The RBD-specific Immunoglobulin G (IgG) antibody was positive in mothers receiving 2 doses of the vaccine and their infants. But the antibody titers were under the positive cut-off threshold for the other 12 women who were vaccinated with a single dose. Women who received both doses of vaccine had significantly higher IgG levels than a single dose of Sinopharm (p = .025). The same result was demonstrated in infants born to these mothers (p = .019).
Conclusion: There was a significant correlation between maternal and neonatal IgG concentrations. Although, receiving both doses of the BBIBP-CorV vaccine (not 1 dose) during pregnancy is highly beneficial for increasing humoral immunity for the mother and fetus.
Keywords: COVID-19; Iran; Sinopharm; antibody; cord blood; maternal mortality; pregnancy; vaccine.